Is ABT-737 legal in Australia?

The laboratory predecessor of navitoclax, used as a senolytic tool compound in mice. No one has ever been given ABT-737 in a published clinical study; it is not orally bioavailable, which is why the orally available analogue was developed and taken into people instead.

ABT-737 is a BH3 mimetic that binds BCL-2, BCL-xL and BCL-w and triggers apoptosis in cells that depend on them. It is the parent compound of navitoclax, which the ovarian cancer investigators describe plainly as the orally available ABT-737 analogue.

Mechanism: Established in cells and in mice: ABT-737 occupies the BH3 binding groove of BCL-2, BCL-xL and BCL-w, releasing BAX and BAK and committing the cell to apoptosis. Senescent cells in mouse tissues upregulate these proteins to survive, which is the basis of the selectivity seen in animal experiments.

Regulatory history: Not approved and not in clinical development. A preclinical research compound with no registered human trial. Its oral analogue navitoclax reached phase 1 and 2 oncology trials and is also unapproved.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for ABT-737 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.